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Abstract 
Objective: To present detailed results of 
our treatment experience in using 
Neuroform Stent-Assisted Coil 
embolization to treat complex cerebral 
aneurysms over 3-year period, emphasizing 
on the technical difficulties, procedure-
related complications, and to evaluate 
midterm results.  
Methods: Patients underwent Neuroform 
stent-assisted coil embolization were 
registered in a database. We assessed 
patients’ history, aneurysm morphology, 
indications for stenting, and technical 
details of the procedures, complications and 
midterm follow-up data. 
Results: This study included twenty-six 
patients with 39 aneurysms. A total of 32 of 
39 aneurysms were treated by Neuroform 
stent-assisted embolization (SAC). Three 
anuerysms stented without coiling, 2 
aneurysms coiled without stenting and 2 
aneuysms surgically clipped. The 
indications for use included broad-necked 
aneurysms (n = 28), giant or large 
aneurysms (n = 6), and fusiform 
aneurysms (n = 5). Of the 32 aneurysms 
treated by Neuroform SAC, we achieved 
complete (100%) and near complete (> 
95%) occlusion in 27 aneurysms, and 
Partial (< 95%) occlusion in 5 aneurysms. 
Follow-up angiographic data avialble in 22 
of 32 aneurysms treated by Neuroform 
SAC (68.7%) (average follow-up, 12 mo; 
range 4–24 mo) demonstrating 
recanalization in 3 aneurysms (13.6%), and 
stable occlusion in 19 aneurysms (86.4%). 
No delayed progressive embolization or in-
stent stenosis observed.  
Conclusion: Neuroform microstent 
system led to a significant evolution in the 
endovascular treatment of complex 
intracranial aneurysms. Our results and 
midterm follow-up showed Neuroform 
stent-assisted coil embolization is safe and 
effective technique in the treatment of 
complex cerebral aneurysms. Although, the 
clinically significant complications are 
uncommon and the evaluation at midterm 
follow-up is encouraging, further studies 
needed to assess the long-term stability and 
durability of the stent. 
Keywords: aneurysm, coil, 
embolization, midterm follow-up, 
neuroform, stent 
Introduction 
The Neuroform stent is self-expandable, 
microcatheter delivered Nitinol stent 
(formed by alloying nickel and titanium (~ 
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50% Ni), is a shape memory alloy with 
superelastic properties) specifically designed 
for application to intracranial vessels. 
Neuroform stent microdelivery system is 
divided into three parts: the self-expanding 
stent itself, a 3F delivery microcatheter, and 
a (2F stabilizing microcatheter) stabilizer. It 
has converted some previously ‘un-
treatable’ aneurysms into endovascular 
amenable lesions. Only few series of 
patients treated with this stent has been 
reported in the literature (6, 11, 21 ,22, 23 
,24, and 25). Our aim is to report in details 
our immediate and avialable midterm 
results in the use of Neuroform microstent 
for the embolization of complex intracranial 
aneurysms. 
Methods - Subjects 
All patients included in this study 
represents an all-inclusive series of patients 
underwent Neuroform SAC embolization 
in our department during a 36-month 
period (December 2004 – December 2007). 
Normally, patients were included when the 
neurointerventionalist advised that the 
aneurysm could not be treated effectively 
with traditional endovascular techniques 
and the risk-to-benefit ratio equal or 
superior to that of microsurgical clipping 
based on the aneurysm location and 
anatomic characteristics combined with the 
patient clinical status and ability to afford 
the treatment expenses  
A total of 26 patients harboring 39 
aneurysms were deemed suitable for 
treatment. There were 11 males and 15 
females ranging in age from 25 to 69 years 
with a mean age of 48.4 years. The patients’ 
demographics are listed in Table 1. 
Twenty-three patients presented with 
ruptured aneurysms (included two 
aneurysms in two different patients were 
presented as recurrence developed after 
primary coil embolization alone) and three 
patients had unruptured aneurysms. 
Regarding those aneurysms’ types, there 
were 28 broad neck aneurysms (dome-to-
neck ratio < 2 or neck diameter > 4-mm), 
6 large aneurysms (dome > 9.5-mm), and 5 
fusiform aneurysms. With respect to the 
broad neck aneurysms, the average dome 
size 3.6-mm, the average neck size 2.6-mm, 
and the average dome-to-neck ratio 1.38.  
Pre-procedural arrangements 
Before SAC procedure started, routinely, 
each patient or his/her family provided 
informed consent for the patient to 
undergo the procedure. 
All patients underwent diagnostic 
cerebral angiography before stent 
placement. Following diagnostic 
angiography, the neurointerventionalist 
determines whether the patient is a suitable 
candidate for the Stent-Assisted Coiling 
(SAC) or not.  
If a patient had unruptured aneurysm or 
was not in the acute stage of aneurismal 
SAH and was selected for stent use before 
the procedure, our anti-coagulation 
regimen consists of Aspirin (Enteric 
Coated) 100 mg and Clopidogrel 75 mg by 
mouth for 3 days were administered. If the 
patient was not selected for stent use before 
the procedure, it was usually administered  
a bolus dose of clopidogrel 225 mg with 
Aspirin 100mg through NGT. After the 
femoral vascular access was obtained, a 
bolus dose of 2000 to 3000 U heparin was 
administrated to achieve an Activated 
Clotting Time (ACT) of twice to treble of 
the baseline. 
 
 
 
Romanian Neurosurgery (2010) XVII 2: 147 – 157          149 
 
 
 
 
Table 1  Summary of patients treated with Neuroform SAC 
 Age  H&H  Sizes Type  Immed. F/U F/U 
Pt.  /sex  Aneurysm D/N of Stent DSA time DSA 
No (yrs) Status grade Location (mm) Procedure Size Results (mth) Results 
1 38/F R II (BN)PComA/L 5.0/3.0 Stent/Coil 4.5x20 C 9 Sta 
   (BN)ICA-OPHTH/L 5.0/3.0 Stent/Coil 4.5x20 C 9 Sta 
2 67/M UR 0 (L)AComA 15/12 Stent/Coil 3.5x20 NC NA  
3 54/F R IV (BN)Basilar 2.0/2.0 Stent only 4.5x15  
   (F)Vertebral/L 2.8/2.0 Stent/Coil 4.5x20 NC NA  
4 43/F R I (BN)ICA-C2/R 3.5/3.5 Stent/Coil 4.0x20 C 6 Sta 
5 50/F R III (BN)ICA-C2/R 5.8/5.2 Stent/Coil 3.5x20 C 11 Sta 
6 45/F R IV (BN)ICA-C4/R 2.4/2.6 Stent/Coil 3.5x20 C 8 Sta 
7 47/M R II (L)Ophth/R 10/5.0 Stent/Coil 4.5x20 C 6 Sta 
   (BN)Ophth/L 5.0/4.0 Stent/Coil 4.5x20 NC 6 Sta 
8 56/F R III (BN)PComA/R 2.5/3.0 Stent/Coil 3.0x20 C NA  
9 52/F R II (BN)ICA-PComA/L 5.5/2.8 Stent/Coil 3.5x15 C 12 Sta 
10 47/F R I (BN)AComA 4.4/2.3 Stent/Coil 3.5x20 C 7 Rec 
11 37/M R II (BN)ICA-C2/R 2.2/1.4 Stent/Coil 4.0x15 P 17 Sta 
   (BN)MCA-M2/R 6.5/3.0 Clipped  
12 62/F R II (BN)AComA/L 3.8/2.0 Coil only  
   (BN)ICA-C6/L 2.1/3.3 Stent/Coil 4.5x20 C 6 Sta 
13 39/M R III (BN)AComA/L 4.2/3.8 Stent/Coil 4.0x20 NC NA  
14 58/F R IV (BN)MCA-M2/R 7.7/3.0 Coil only  
   (BN)ICA-C3/R 2.0/1.3 Stent/Coil 4.0x20 C NA  
15 32/M R II (BN)Ophth/L 4.0/3.0 Stent/Coil 4.5x20 C 11 Sta 
16 54/M R II (BN)AComA 4.7/2.7 Stent/Coil 4.0x15 P 24 Sta 
   (BN)PComA/L 5.2/3.1 Stent/Coil 4.0x15 C 24 Sta 
   (BN)Ophth/L 3.1/3.1 Stent/Coil 4.0x15 P 24 Sta 
17 69/M RE II (L)PComA/R 10.3/4.1 Stent/Coil 4.5x20 C NA  
18 25/F R II (BN)ICA-Ophth/L 6.4/3.2 Stent/Coil 3.5x20 C 4 Sta 
19 26/M RE IV (L)AChoA/L 9.5/1.6 Stent/Coil 4.5x20 C NA  
20 54/F R II (BN)PComA/R 6.3/6.0 Stent/Coil 4.5x15 C NA  
21 48/F R II (L)PComA/R 12/3.0 Stent/Coil 4.5x20 NC 12 Rec 
22 69/M UR 0 (F)ICA-C3/L 9.7/8.0 Stent/Coil 4.5x20 P  NA  
   (F)ICA/R 9.0/5.0 Stent only 4.5x15  
   (F)Basilar 26/20 Stent only 4.5x20  
23 51/M R IV (F)MCA-M2/R 7.0/10.1 Stent/Coil 3.0x20 P 14 Rec 
   (BN)ICA-C2/R 3.7/3.7 Stent/Coil 4.0x20 NC 14 Sta 
   (BN)PComA/R 3.0/2.1 Clipped  
24 41/F RE 0 (L)ICA-OPHT/L 11/4.2 Stent/Coil 4.0x20 C 24 Sta 
25 39/M R II (BN)MCA-M2/R 7.2/5.4 Stent/Coil 4.5x15 C NA  
26 56/F R II (BN)ICA-A2/L 4.0/3.0 Stent/Coil 4.5x20 C 8 Sta 
   (BN)ICA-A3/R 5.0/4.0 Stent/Coil 4.5x20 C 8 Sta 
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After the procedure, heparinization was 
not reversed. Subcutaneously 0.4 ml Low 
Molecular Weight Heparin (LMWH) twice 
a day, usually administered for three days 
postoperative. Patients were continued on 
Clopidogrel 75 mg for 6 weeks and aspirin 
100mg for six months postoperatively. 
Indications  
The indications for stent placement were 
categorized as broad neck aneurysm, 
fusiform/dissecting aneurysm, large/giant 
aneurysm, residual aneurysms after primary 
coil embolization and aneurysms with 
protruded coils (i.e., for patients in whom 
coils prolapsed or may prolapse into the 
parent vessel). 
Stent and size estimation 
Stents are sized on the basis of the 
largest diameter of the parent vessel in 
which the stent is to be deployed in. 
However, special attention should be paid 
to slightly oversized rather than undersized 
(we usually oversized by 0.5 – 1.0mm) with 
an overlap of at least 5 mm on each side of 
the neck of the aneurysm.  
Results 
A total of 26 patients (11 males and 15 
females ranging in age from 25 to 69 years 
with a mean age of 48.4 years) harboring 39 
aneurysms were deemed suitable for 
Neuroform SAC treatment. Twenty-three 
patients presented with aneurysmal Sub-
Arachnoid Hemorrhage (SAH): whereas, 
three patients were presented by symptoms 
not related to the aneurysmal rupture. In 
regard to the patients presented with 
Aneurysmal SAH, 2 patients were Hunt 
and Hess Grade I, 13 patients were grade II, 
3 patients were grade III, and 5 ptients were 
grade IV.  
In this study group, we used a total of 35 
Neuroform stents., Twenty-three 
Neuroform stents implanted to cover the 
neck of 23 broad neck aneurysms, 6 
Neuroform stents implanted to cover the 
neck of 6 large aneurysms and 3 
Neuroform stents overlap 3 fusiform 
aneurysms: meanwhile, we used 3 stents to 
cover the neck of 1 broad neck aneurysm 
and to overlap 2 fusiform aneurysms 
without coiling embolizatiion.  
The occlusion rates evaluation were 
ranked in complete occlusion, near 
complete occlusion and partial occlusion as 
100%, > 95%, and <95% respectively. Of 
those 32 aneurysms treated by Neuroform 
SAC, complete (100%) occlusion achieved 
in 21 aneurysms (65.6%), and near 
complete occlusion (>95%) achieved in 6 
aneurysms (18.7%), and partial occlusion 
(<95%) achieved in 5 aneurysms (15.6%). 
Table 2 
Complications 
Two clinically evident thromboembolic 
complications occurred (patient 12 and 23) 
after stent placement. Patient 12 
experienced right hemi paresis upon waking 
after the deployment of stent within the left 
ICA to support the coil embolization of a 
broad neck aneurysm. However, both of 
the patients made good functional recovery. 
Those patients were treated in the context 
of acute SAH without pretreatment with 
antiplatelet medications. No aneurismal 
rupture was encountered during the 
prcedure, and no mortality related to the 
procedure. 
Stent displacement encountered in one 
patient (patient 22). In this case, the initial 
plan was to deploy the second stent within 
the first one to achieve a satisfactory overlap 
over the aneurysm. Unfortunately, the first 
stent was displaced after the deployment. In 
this instance, the distal portion of the stent 
was displaced into the aneurysm sac located 
in the upper trunk of the basilar artery. The 
delivery system could not be navigated 
easily beyond the landing zone from the 
parent vertebral artery due to the severe 
 
 
 
Romanian Neurosurgery (2010) XVII 2: 147 – 157          151 
 
 
 
turtuosity between the aneurysm and the 
distal part of the parent artery which 
resulted in the displacement of the distal 
portion of the stent into the aneurysm sac.   
Follow-up angiography 
Follow-up angiographic data are 
available in only 22 of 32 aneurysms 
(68.7%) treated by Neuroform SAC 
embolization. The high number of follow-
up dropouts (31%) was due to the 
uncomplying with doctor’s recmmended 
fullow-up angiography by some patients. 
The average follow-up time is 12 months 
(range, 4–24 months). In the available 
follow-up angiographies, no cases found to 
develop in-stent stenosis in this study 
group. No change was observed in 19 
aneurysms:however, the size of the residual 
aneurysm increased in 3 patients (patient 
10, 21, and 23) Table 2. With respect to the 
anuerysms treated with stent alone, follow-
up angiographies were are not available in 
all anuerysms.  
Illustrative cases 
Patient 24  
A 41-year-old woman presented with 
headache. Cerebral arteriogram 
demonstrated a large aneurysm in the left 
ICA-Ophth junction (Figure 1 A). Initially, 
the aneurysm was coiled only with 
complete occlusion achieved (Figure 1 B). 
A two-year follow-up arteriogram revealed 
recurrence. This recurred aneurysm had a 
poor fundus-to-neck ratio, so she was 
deemed a good candidate for stent-assisted 
coiling (Figure 1 C & D). A Neuroform 
(4x20) stent was successfully deployed in 
the optimal segment across the aneurysm 
neck. Subsequent GDC coil sat safely in the 
aneurysm sac (Figure 1 E & F).  
Table 2  Summary of patients treated with Neuroform Sac 
2.1.        39   ANEURYSMS TREATMENT   
STENT/COIL STENT COIL CLIP 
32 3 2 2 
2.2.   OCCLUSION ACHIEVED IN 32 ANEURYSMS TREATED BY NEUROFORM SAC 
PARTIAL(<95%) NEAR COMPLETE(>95%) COMPLETE (100%)  
5 6 21  
2.3.    FOLLOW-UD DATA OF 22 ANEURYSMS TREATED BY NEUROFORM SAC 
PROGRESSIVE  RECANALIZATION STABLE IN-STENT STENOSIS 
0 3 19 0 
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D                                                       E                                                          F 
      
G                                                        H 
Figure 1  Arteriogram of a 41-year-old woman presented with headache. A. left ICA arteriogram demonstrating 
large aneurysm involving the left ICA-Ophth. artery take-off. B, control arteriogram showing complete 
occlusion after coil embolization. C&D, tow-year follow-up arteriogram revealed residual filling. E, post-
stenting control arteriogram showing successful stent deployment and coiling with complete occlusion. F, 
unsubtracted film showed the stent and the coils are still in the optimal position. G, Control arteriogram after 
NF (4x20) stenting demonstrating complete (100%) occlusion of the aneurysm. H, two-year follow-up 
arteriogram demonstrating stable embolization of the recurrent aneurysm. 
 
Immediate arteriogram showed complete 
occlusion (Figure 1 G) Two-year follow-up 
arteriogram revealed stable occlusion (Figure 
1 H). 
Patient 10 
A 47-year-old woman presented with 
SAH Hunt & Hiss grade I. Diagnostic 
cerebral angiography revealed a broad neck 
aneurysm in the right ICA at the PComA 
take-off (Figure 2 A & B). This aneurysm 
demonstrated a poor dome-to-neck ratio 
that made her a good candidate for SAC 
embolization. A Neuroform (3.5x20) stent 
was successfully deployed in the optimal 
segment across the aneurysm neck. 
Subsequent Cordis Helical Fill coil sat safely 
in the aneurysm sac (Figure 2 C & D). Post-
procedural situation was uneventful. Seven-
month follow-up arteriogram revealed 
residual filling of recurrence. 
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A                                                                          B 
      
C                                                                           D 
      
E                                                                             F 
Figure 2  Imaging study of a 47-year-old woman presented with SAH Hunt & Hiss grade I. A, B, Cerebral 
arteriogram demonstrated a wide-neck aneurysm in the right ICA at the Posterior communicating artery take-
off. C, post NF (3.5X20) stent-assisted coil embolization subtracted arteriogram showed complete 
occlusion(100%). D,Unsubstracted anteroposterior image showed the stent and coil in the optimal position. E, 
Follow up anteroposterior cerebral arteriogram revealed residual filling of recurrence. F, Anteroposterior 
unsubtracted film showed the stent and the coils are still in the optimal position. 
 
Discussion 
The goal of endovascular aneurysm 
treatment is to eliminate the aneurysm 
from the blood circulation and to prevent 
the flow of blood into the aneurysm by 
filling the aneurysm sac with embolization 
material. (1) The introduction of three-
dimensional coils, which retain a complex 
shape after detachment, provided some 
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additional flexibility with respect to the 
ability to treat patients with complex 
aneurysms (2). However, it is not feasible 
to perform a coiling procedure for some 
aneurysms (5% to 14.5 % of cases), (3, and 
4) because unusual tortuosity of the vessels 
renders access difficultly or because the 
contours of the aneurysm do not permit the 
coils to sit safely inside. Therefore, larger 
aneurysms and aneurysms with wider necks 
typically had lower rates of successful 
occlusion. (5, 6, 7) 
To overcome the problem of complex 
morphology aneurysms coiling, Moret et al. 
(8) pioneered the balloon remodeling 
technique that enables temporary 
remodeling of the aneurysm neck during 
coil delivery. We used this technique in 
seven patients of our study series (e.g. 
Patient 9 Figure 1). 
After the first report of endovascular 
stent-supported coil embolization for the 
treatment of experimental carotid sidewall 
aneurysms in animals in 1994 (9, 10), 
Higashida reported the first use of stent in 
the human intracranial circulation to 
prevent backward protrusion of 
electrodetachable coils in 1997. 
(11) Since then, series of patients treated 
with self-expandable stents devoted to 
intracranial aneurysms such as the 
Neuroform stent (9-11, 12, 13) the Cordis 
Enterprise stent (14) (Cordis Endovascular, 
Miami Lakes, FL) or the Balt Leo stent (15) 
(Balt, Montmorency, France) have been 
reported. 
As reported in other series (9, 12, 13, and 
16) we observed in our practice that the 
navigation of the stent delivery system to 
and beyond the landing zone was not 
problematic; the actual deployment of the 
stent is frequently difficult because of 
binding of the microwire, the stabilizer, and 
the stent delivery catheter. Lylyk et al. (16) 
reported difficulties in placing the 
Neuroform stent in 31% of patients, mostly 
at the beginning of their experience. A 
second generation of devices resolved this 
limitation. Fiorella et al. (12) confirmed 
that using the second-generation 
(Neuroform 2) delivery system alleviated 
the technical problems with stent delivery 
and deployment encountered in their initial 
results (17).However, the technical 
advances in the newer generation of this 
stent (Neuroform 3), which is mounted in 
a more suitable delivery system, 
significantly facilitated this stent 
deployment.  
Several case reports an initial practice 
with aneurysm stenting have been 
published, including the use of stents in 
fusiform and dissecting aneurysms (18, 19, 
and 20). These reports showed satisfying 
immediate anatomical exclusion of the 
aneurysm and safety since the procedure-
related morbidity and mortality rates were 
low. Our series corroborates that the 
Neuroform stent was effective in providing 
a level of parent vessel protection adequate 
to allow satisfying packing in the complex 
aneurysms that were not amenable to 
conventional endovascular treatment. 
Liang et al reported their clinical 
experience and 5 year follow-up results 
using Neuroform stent-assisted coiling of 
intracranial aneurysms for 107 patients, 
they achieved complete occlusion in 57.2%, 
neck remnant in 27.3% and incomplete 
occlusion in 15.5%. (23) Biondi et al 
angiographic results showed 14 (35%) 
aneurysm occlusions, 18 (45%) neck 
remnants, and eight (20%) residual 
aneurysms in 40 aneurysms treated with 
stent-assisted coiling (24). Eduardo 
Wajnberg et al reported their experience 
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with the Neuroform stent for the treatment 
of 24 wide-necked intracranial aneurysms, 
their immediate angiography demonstrated 
complete occlusion in 70.8%, neck 
reminant in 16.6% and incomplete 
occlusion 12.5%. (25) 
In our study group, Immediate 
Angiographic Occlusion Rates of those 32 
aneurysms treated with Neuroform SAC 
demonstrated complete (100%) occlusion 
in 21 aneurysms (65.6%), near complete 
occlusion (>95%) in 6 aneurysms (18.7%), 
and partial occlusion (<95%) in 5 
aneurysms (15.6%). However, in our 
practice small aneurysms were among the 
most difficult aneurysms to achieve 
complete occlusion faced in our study 
group. The small wide-neck aneurysm did 
not provide enough space to hold coils and 
microcatheter tip during coil delivery which 
pushes the microcatheter out of the sac 
before coil detachment. 
In other series, morbidity ranged from 
5.8 to 20% and mortality from 2.1 to 8.9% 
(9, 11, 17, and 16). In our series, we 
observed a relatively low rate of 
complications (7.6% morbidity and 0% 
mortality), which appeared unrelated to the 
stenting procedures. 
Obviously, the comparison of 
angiographic outcomes across reported 
series is difficult. A standard definition of 
what constitutes complete occlusion and 
residual aneurysm filling is lacking and 
quantification and analysis of the results is 
subjective (26). In addition, few papers 
report angiographic follow-up in stenting 
procedures for aneurysms. However, we 
believe that the high success rate of the 
combined stenting/coiling treatment in our 
study group is appreciated to the small 
number of analyzed patients with their 
relatively short follow-up time that may 
produce a positive bias in this study. 
Further more, the high number of follow-
up dropouts (31%) due to uncomplying 
with doctor’s recmmended fullow-up 
angiography by some patients could also 
dramatically change the mortality/morbidity 
rates that had been presented. 
Our follow-up angiography 
demonstrated that in no case progressive 
occlusion or in-stent stenosis found in 
aneurysms treated with Neuroform SAC. 
Whereas Murayama et al (6), reported rates 
of 30 and 22% in large and small, wide-
necked aneurysms, respectively. Murayama 
et al relatively high rate of progressive 
thrombosis may have contributed to the 
bioactive coils (Matrix Coil). Fiorella et al. 
(12) reported delayed and severe in-stent 
stenosis in three of 64 (4.7%) patients. In 
our series, asymptomatic stenosis of the 
parent artery at the proximal end of the 
stent was not observed. However, our 
available follow-up data revealed three cases 
with growth residual that is highly 
attributed to coil compaction process.  
The thrombogenicity of the Neurofrom 
stents represents an important limitation 
with respect to the treatment of aneurysm, 
particularly those treated in the context of 
acute SAH (27). Dual anti-platelet regimens 
have been established to be superior to 
aspirin therapy alone (28). Clopidogrel is 
generally used because of its more potent 
platelet-anti-platelet effect, faster onset of 
action, and lower incidence of significant 
adverse effects (29).  
In our practice, If a patient had 
unruptured aneurysm or was not in the 
acute stage of aneurismal SAH and was 
selected for stent use before the procedure, 
Aspirin 100 mg and Clopidogrel 75 mg by 
mouth for 3 days were administered. If the 
patient was not selected for stent use before 
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the procedure or in the acute stage of SAH, 
it was usually administer a bolus dose of 
clopidogrel 225 mg with Aspirin 100mg 
through the NGT. After the femoral 
vascular access was obtained, a bolus dose 
of 2000 to 3000 U heparin was 
administrated to achieve an Activated 
Clotting Time (ACT) of twice to treble of 
the baseline.  
Low Molecular Weight Heparins 
(LMWH) have been shown in recent years 
to be more effective and safer than heparin 
in the prevention of thromboembolic 
events after coronary angioplasty and stent 
placement. (30, 31) n our practice, upon 
completion of the intervention, heparin was 
discontinued and anticoagulation was 
preserved for 3 days with low molecular 
weight heparins (LMWH). Patients were 
continued on Clopidogrel 75 mg for 6 
weeks and aspirin 100mg for six months 
postoperatively.  
Conclusion 
Neuroform microstent system led to a 
significant evolution in the endovascular 
treatment of complex intracranial 
aneurysms. Our results and midterm 
follow-up showed that Neuroform stent-
assisted coil embolization is a safe and 
effective technique in the treatment of the 
complex cerebral aneurysms. Although ,the 
clinically significant complications are 
uncommon and the evaluation at midterm 
follow-up are encouraging, further studies 
are needed to assess the long-term stability 
and the durability of the stent. 
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